Predictive biomarkers in lymphoma: a systematic research review

Abstract

Lymphoma is a diverse group of blood cancers originating in the lymphatic system, with varying clinical presentations and prognoses. Identifying and utilizing predictive biomarkers in lymphoma can significantly impact the management and outcome of patients. For instance, the presence of the BCL2 gene rearrangement in follicular lymphoma is associated with a poorer prognosis, while the expression of the CD20 protein in diffuse large B-cell lymphoma is a predictor of response to rituximab. These biomarkers are molecular or cellular indicators that can help forecast disease progression, therapeutic response, and patient prognosis. This abstract provides an overview of the current landscape of predictive biomarkers in lymphoma, focusing on their role which can help physicians to build personalized treatment strategies. We explore key types of biomarkers, including genetic mutations, protein expressions, and cellular markers, that have shown potential in predicting treatment response and survival outcomes across different lymphoma subtypes. Furthermore, we delve into recent advancements in biomarker discovery through high-throughput technologies such as next-generation sequencing and their strategic integration into clinical practice. The use of predictive biomarkers not only enhances the precision of treatment regimens but also contributes to better risk stratification and patient monitoring. The future of this field involves the refinement of biomarker panels for improved predictive accuracy and the exploration of novel targets for therapy. The strategic application of predictive biomarkers in lymphoma presents promising opportunities for optimizing patient care and advancing precision medicine in hematological malignancies.